Is Chemed’s Removal From Key Russell Growth Indices Altering The Investment Case For CHE?

• On 27 June 2026, Chemed Corporation (NYSE: CHE) was removed from multiple Russell growth and defensive indices, including the Russell 1000 Growth and Russell 3000 Growth benchmarks, following the latest index reconstitution.
• This broad index exclusion may alter how passive and benchmark-aware investors gain exposure to Chemed, potentially affecting its shareholder base composition and trading patterns.
• We’ll now examine how Chemed’s widespread removal from key Russell growth indices interacts with its existing investment narrative and outlook.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Chemed Investment Narrative Recap

To own Chemed, you need to believe that VITAS can manage Medicare exposure while Roto Rooter stabilizes demand and margins, supporting solid cash generation. The broad Russell growth index removals may shift Chemed’s shareholder mix and liquidity, but they do not directly change the core near term catalysts around hospice cap management or the key risk of reimbursement and mix pressure at VITAS.

The most relevant recent development alongside Chemed’s index removal is its continued use of share repurchases, with 500,000 shares bought back in Q1 2026 for US$197.68 million. This capital return sits against softer recent earnings trends and Medicare cap pressures, making it important to watch whether buybacks remain accretive if reimbursement headwinds, Roto Rooter competition, or higher funding costs from the new credit facility weigh more heavily on future results.

Yet behind this steady capital return story, investors should be aware that reimbursement and patient mix risk at VITAS could still…

Read the full narrative on Chemed (it’s free!)

Chemed’s narrative projects $3.1 billion revenue and $386.5 million earnings by 2029. This requires 6.6% yearly revenue growth and an earnings increase of about $126.7 million from $259.8 million today.

Uncover how Chemed’s forecasts yield a $446.50 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts once expected Chemed’s earnings to reach about US$417.5 million, but after this broad Russell removal, you should consider how that bullish revenue and margin path, and the risk of renewed Medicare cap exposure, might look very different.

Explore 4 other fair value estimates on Chemed – why the stock might be worth as much as 47% more than the current price!

Reach Your Own Conclusion

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]